Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.75 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607463 | 0.92 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL16702081 | 0.92 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL6936022 | 0.88 | HSP90AA1 (0.91) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL18123496 | 0.88 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1 | |
| SCHEMBL16702095 | 0.87 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16702631 | 0.87 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL16702167 | 0.87 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1 | |
| SCHEMBL16710407 | 0.86 | HSP90AA1 (0.86) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL1606209 | 0.85 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL1606231 | 0.85 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585267-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | The University of Kansas (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-3068778-B1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIV KANSAS (US) | 2025-02-19 | — | — | EP | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3068778-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | The University of Kansas (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015070238-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070238-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885KDM4E 1906/4885 |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885KDM4E 1792/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885KDM4E 1792/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | HSP90AA1 2/4885HSP90AB1 3/4885KDM4E 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.